MY PATHWAY: AN OPEN-LABEL PHASE IIA STUDY EVALUATING TRASTUZUMAB/PERTUZUMAB, ERLOTINIB, VEMURAFENIB/COBIMETINIB, VISMODEGIB, ALECTINIB, AND ATEZOLIZUMAB IN PATIENTS WHO HAVE ADVANCED SOLID TUMORS WITH MUTATIONS OR GENE EXPRESSION ABNORMALITIES PREDICTIVE OF RESPONSE TO ONE OF THESE AGENTS
My Pathway: Study Evaluating Drug in Patients with Advanced Solid Tumors with Mutations or Gene Expression Abnormalities
Sponsor: Genentech, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAN9701
U.S. Govt. ID: NCT02091141
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: Four different treatment regimens will be evaluated simultaneously in groups of patients who have advanced solid tumors that has progressed following administration of standard of care treatment, or for whom no standard therapy exists, or for whom therapies that will convey clinical benefit are not available, and in whom a trial of targeted therapy is considered the best available treatment option.
This study is closed
Investigator
Emerson Lim, MD
Do You Qualify?
Have you been diagnosed with progressive cancer? Yes No
Have you previously been treated with Erlotinib, Trastuzumab and Pertuzumab, Vemurafenib, or Vismodegib in the past? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162